Aastrom Biosciences, Inc. company was founded in 1989 and is headquartered in Ann Arbor, Michigan. Aastrom Biosciences, Inc. is a regenerative medicine company and focuses on the clinical development of autologous cell products for the repair or regeneration of multiple human tissues, based on its Tissue Repair Cell (TRC) technology. The Company’s preclinical and clinical product development programs utilize patient-derived bone marrow stem and early progenitor cell populations and are investigated for their ability to aid in the regeneration of tissues, such as cardiac, vascular and bone. TRC-based products have been used in over 350 patients, and its stages of development are Cardiac regeneration includes Cardiac Repair Cells (CRCs); Dilated cardiomyopathy (DCM) (severe heart failure); Vascular regeneration includes Vascular Repair Cells (VRCs); Critical limb ischemia (CLI); Bone regeneration includes Bone Repair Cells (BRCs); Osteonecrosis of the femoral head; Non-union fractures, and Maxillofacial.

MonoSol Rx, Inc. company develops thin film versions (about the size of a postage stamp) of new and existing prescription and over-the-counter drugs for colds, nausea, pain, and other ailments. MonoSol creates its thin film products, which are easier to take than tablets or capsules, primarily through partnerships with other pharmaceutical companies. Brands of current drug candidates for its thin film strips include Ambien, a sleep aid, and Lexapro, an anti-depressant. The company has a manufacturing facility in Portage, Indiana, and focuses on creating products for US, Europe, and Asia/Pacific markets.

Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

For biotechnology and pharmaceutical companies whose next big breakthrough is stuck in the test tube, Oxford Therapeutics Consulting could have the answer. The product development consulting firm offers strategic planning and product management for biotechs and pharmas that are short on staff and experience in bringing a new product through the lengthy development pipeline. Oxford Therapeutics' team of consultants work primarily with smaller companies on products such as anticancer agents, antibacterial and antiviral compounds, and therapeutic vaccines.

Luitpold Pharmaceuticals earns its gold from the businesses of drugs and medical devices. Luitpold markets and manufactures injectable products used to treat an array of ailments including kidney disease. Luitpold also manufactures materials used in dental bone grafting and bone regeneration and treatments for equine and canine joint diseases. The company, which targets its products primarily to hospitals and clinics in US and Canadian markets, operates through four divisions: American Regent, Luitpold Animal Health, Osteohealth, and Contract Manufacturing. Originally a German company named after a Bavarian prince, Luitpold is a subsidiary of one of Japan's largest pharmaceutical companies, Daiichi Sankyo.

Novartis AG company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis AG, through its subsidiaries, engages in the research, development, manufacture, and marketing of healthcare products worldwide. Its Pharmaceuticals division engages in the research, development, manufacture, distribution, and sale of pharmaceuticals in various therapeutic areas, including cardiovascular and metabolism; oncology; neuroscience and ophthalmics; respiratory; and immunology and infectious diseases. Novartis company's Vaccines and Diagnostics division offers preventive vaccines and diagnostic tools. This division provides influenza, meningococcal, pediatric, and traveler vaccines; and blood testing and molecular diagnostics to prevent the spread of infectious diseases. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; anti-infectives; protein or biotechnology-based products; and cytotoxic products, as well as offers biotech manufacturing services to other companies on a contract basis. Novartis company's Consumer Health division consists of three business units: over-the-counter medicines (OTC), Animal Health, and CIBA Vision. OTC offers readily available consumer medicines. Animal Health provides veterinary products for farm and companion animals. CIBA Vision manufactures contact lenses and lens care products. Novartis AG has a strategic alliance with Intercell AG to develop vaccines; and a strategic partnership with Lonza, a Swiss pharmaceuticals manufacturing company.

Sanofi-Aventis Deutschland boasts itself as one of the largest pharmaceutical businesses in the country. A subsidiary of French giant Sanofi-Aventis, the company manufactures and markets prescription and over-the-counter drugs. Along with its Lantus and Insuman insulin products, Sanofi-Aventis Deutschland produces Plavix and Lovenox. The company also dedicates much of its efforts on research and development at its Frankfurt, Germany headquarters and is focused on metabolic illnesses such as diabetes, as well as cancer and cardiovascular diseases.

Founded in 1929, the not-for-profit organization is a leading researcher of human diseases, their causes, and their potential cures. Much of its research into mammalian genetics is focused on mice, which share a similar genetic makeup to humans. In addition to its own research in areas such as cancer, immunology, and metabolic disease, the organization maintains colonies of mice and supplies them under the brand name JAX to other laboratories around the globe. Additionally, The Jackson Laboratory offers educational programs -- including internships, workshops, and predoctoral programs -- for both current and future scientists.

Elan Pharmaceuticals is part of the the brains behind the brawn of drugmaker Elan Corporation. The US-based subsidiary provides research and discovery services, such as the identification and development of new drug candidates, to its Irish parent, which specializes in treatments for neurological and autoimmune diseases, as well as severe pain and infectious disease medications. The company investigates possible treatments for diseases such as Alzheimer's disease, Parkinson's disease, and multiple myeloma. The subsidiary also handles marketing of Elan's approved products in the US, including multiple sclerosis/Crohn's disease treatment Tysabri and chronic pain medication Prialt.

Poniard Pharmaceuticals was founded in 1984 and is headquartered in South San Francisco, California. Poniard Pharmaceuticals, Inc., together with its subsidiary, NeoRx Manufacturing Group, Inc., focuses on the development and commercialization of oncology products for people with cancer. Its lead platform product candidate, Picoplatin, is a platinum-based cancer therapy that is designed to overcome platinum resistance associated with chemotherapy in solid tumors. Picoplatin is being studied in various cancer indications, combinations, and formulations. Poniard Pharmaceuticals is conducting a phase III clinical trial of intravenous picoplatin in small cell lung cancer; two phase II clinical trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers; and a clinical trial of oral picoplatin in solid tumors. The company was formerly known as NeoRx Corporation and changed its name to Poniard Pharmaceuticals, Inc. in June 2006.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.